Vascular protection in diabetes: A pharmacological view of angiotensin II type 1 receptor blockers

Acta Diabetologica

Volumn 42, Issue SUPPL. 1, 2005, Pages

  Kintscher, U ^a   Unger, T ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adiponectin; Angiotensin type 2 receptor; Diabetes mellitus; Peroxisome proliferator activated receptor gamma; Telmisartan; Vascular disease

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ADIPOCYTOKINE; ADIPONECTIN; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; EPROSARTAN; GLITAZONE DERIVATIVE; IRBESARTAN; LOSARTAN; OLMESARTAN; PARTIAL AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; TELMISARTAN; VALSARTAN; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE;

ADIPOGENESIS; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SENSITIZATION; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME; VASCULARIZATION; DIABETIC ANGIOPATHY; PHYSIOLOGY; REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; INSULIN RESISTANCE; PPAR GAMMA; RENIN-ANGIOTENSIN SYSTEM;

EID: 18744379491     PISSN: 09405429     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00592-005-0178-y     Document Type: Article

References (52)

1. American Diabetes Association (2004) American Diabetes Association: clinical practice recommendations 2004. Diabetes Care 27[Suppl 1]:S1-S143
2. Chung O, Unger T (1999) Angiotensin II receptor blockade and end-organ protection. Am J Hypertens 12[2 Pt 1]:S150-S156
3. Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM (2000) Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 101:1586-1593
4. Makris TK, Stavroulakis GA, Krespi PG, Hatzizacharias AN, Triposkiadis FK, Tsoukala CG, Votteas VV, Kyriakidis MK (2000) Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am J Hypertens 13:783-788
5. Resnick LM, Lester MH (2002) Differential effects of antihypertensive drug therapy on arterial compliance. Am J Hypertens 15:1096-1100
6. Bragulat E, Larrousse M, Coca A, de la Sierra A (2003) Effect of long-term irbesartan treatment on endothelium-dependent vasodilation in essential hypertensive patients. Br J Biomed Sci 60:191-196
7. 2 receptor in hypertension. Am J Hypertens 13[6 Pt 2]:62S-67S
8. 2 receptors: regulation, signalling and function. Blood Press 12:70-88
9. Fournier A, Messerli FH, Achard JM, Fernandez L (2004) Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 43:1343-1347
10. 2 receptor. J Pharmacol Exp Ther 307:1171-1178
11. Sohn HY, Raff U, Hoffmann A, Gloe T, Heermeier K. Galle J, Pohl U (2000) Differential role of angiotensin II receptor subtypes on endothelial superoxide formation. Br J Pharmacol 131:667-672
12. 2 receptors in modulating coronary microvascular function. Circ Res 92:322-329
13. 2 receptor in blood pressure regulation and therapeutic implications. Am J Hypertens 14[6 Pt 2]:S98-S102
14. Brewster UC, Perazella MA (2004) The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 116:263-272
15. Chung O, Unger T (1998) Unopposed stimulation of the angiotensin AT2 receptor in the kidney. Nephrol Dial Transplant 13:537-540
16. 2 receptor in the kidney: role in health and disease. Semin Nephrol 24:93-100
17. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, for the RENAAL Study Investigators (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869
18. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P, for the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878
19. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, for the Collaborative Study Group (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860
20. Viberti G, Wheeldon NM (2002) Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 106:672-678
21. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE study group (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995-1003
22. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363:2022-2031
23. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M (2001) Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38:884-890
24. Okada K, Hirano T, Ran J, Adachi M (2004) Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats. Hypertens Res 27:293-299
25. Picard F, Auwerx J (2002) PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 22:167-197
26. Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Magar R, Martin J (2002) Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 24:378-396
27. Hsueh WA, Law RE (2001) PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol 21:1891-1895
28. Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM, Libby P, Plutzky J, Luster AD (2000) Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 164:6503-6508
29. Jackson SM, Parhami F, Xi XP, Berliner JA, Hsueh WA, Law RE, Demer LL (1999) Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 19:2094-2104
30. Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, Duriez P, Staels B (1999) Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 85:394-402
31. Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA (1996) Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 98:1897-1905
32. Ricote M, Huang JT, Welch JS, Glass CK (1999) The peroxisome proliferator-activated receptor (PPARgamma) as a regulator of monocyte/macrophage function. J Leukoc Biol 66:733-739
33. Kintscher U, Goetze S, Wakino S, Kim S, Nagpal S, Chandraratna RA, Graf K, Fleck E, Hsueh WA, Law RE (2000) Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur J Pharmacol 401:259-270
34. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK (2000) Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106:523-531
35. Collins AR, Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, Palinski W, Hsueh WA, Law RE (2001) Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 21:365-371
36. Pershadsingh HA (2004) Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin Investig Drugs 13:215-228
37. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, Lehmann JM (1997) Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA 94:4318-4323
38. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 43:993-1002
39. Schupp M, Janke J, Clasen R, Unger T, Kintscher U (2004) Angiotensin type 1 receptor blockers induce peroxisome proliferators-activated receptor-γ activity. Circulation 109:2054-2057
40. Danforth E Jr (2000) Failure of adipocyte differentiation causes type II diabetes mellitus? Nat Genet 26:13
41. Zhao Y, Unger, Kintscher U (2003) Angiotensin II induces PPARgamma in PC12 cells via AT2 receptor activation [abstract]. Hypertension 42:389
42. Stefan N, Stumvoll M (2002) Adiponectin - its role in metabolism and beyond. Horm Metab Res 34:469-474
43. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946
44. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y (2002) Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8:731-737
45. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ (2003) Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 278:45021-45026
46. Ouchi N, Kihara S, Arita Y, Okamoto Y Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y (2000) Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 102:1296-1301
47. Clasen R, Sprang C, Schupp M, Unger T, Kintscher U (2003) Angiotensin type 1 receptor antagonism induces adiponectin expression in adipocytes. Hypertension 42:634
48. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K (2003) Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42:76-81
49. Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, Shimomura I (2003) Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52:1655-1663
50. Chinetti G, Zawadski C, Fruchart JC, Staels B (2004) Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR. Biochem Biophys Res Commun 314:151-158
51. Weber M (2003) The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) programme. J Hypertens 21[Suppl 6]:S37-S46
52. Teo K, Yusuf S, Anderson C, Mookadam F, Ramos B, Hilbrich L, Pogue J, Schumacher H, The ONTARGET/TRANSCEND Investigators (2004) Rationale, design and baseline characteristics of two large, simple randomized trials evaluation telmisartan, ramipril and their combination in high-risk patients: the ONTARGET/TRANSCEND trials. Am Heart J 148:52-61